Intravenous iron saccharate in hemodialysis patients receiving r-HUEPO

Abstract EN

A study was undertaken to evaluate the safety and efficacy of iron saccharate in regular hemodialysis (HD) patients receiving r-HuEPO.

A total of 109 patients (57 males, 52 females, mean age 34.1 + 11.7 years) were included in the study, 64 of whom were iron deficient.

The patients were divided into two groups.

Group I (n = 58) received high dose iron saccharate (500 mg), intravenously (i.v.) (1-2 doses), and Group II (n = 51) received low dose iron saccharate (100 mg), i.v., thrice per week (5-10 doses).

Results at four weeks showed a significant increment in hemoglobin (Hb), hematocrit (Hct), and serum ferritin in both groups.

Two patients developed headache, fever and urticaria, and three patients developed fever in group I.

None of the patients in group II developed any adverse reaction.

Intravenous iron supplementation with iron saccharate in HD patients showing poor response to r-HuEPO, produced satisfactory Hct levels without major side effects and without the need to increase the dose of r-HuEPO.

Commonly observed side effects were not seen with the low dose regimen.